Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Overview of attention for article published in Journal of Hematology & Oncology, October 2012

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 62 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

NEW THERAPEUTIC STRATEGIES AGAINST BLOOD CANCER

Application WO-2017050849-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.